Brightlands Venture Partners Research
Investment Thesis
Brightlands Venture Partners (BVP) invests in innovative, science-based companies tackling global structural challenges across health, agrifood, and renewable chemistry systems. Rooted at the intersection of research, industry, and entrepreneurship, BVP partners with founders to translate technological breakthroughs into enduring, scalable companies. The firm's stated belief is that "system-level change starts small": every investment begins as a ripple that, through execution, adoption, and long-term partnership, can grow into a wave that reshapes markets and strengthens essential systems. BVP is classified as an SFDR Article 9 fund, with sustainable investment as its explicit objective, and evaluates impact alongside commercial performance from initial investment through exit.
Sector Focus
BVP concentrates on three investment themes:
- Health — MedTech, HealthTech, and EnablingTech addressing rising costs, chronic illness, and workforce shortages in European healthcare, guided by an impact framework rooted in the Quadruple Aim.
- AgriFood — Agritech and food-system innovation transitioning farming from extractive to regenerative practices, addressing chemical dependence, emissions, water inefficiency, and food vulnerability.
- Renewable Chemistry — Recycling and circularity, bio-based products and processes, designed-to-recycle materials, low-carbon technology, and bio-based chemicals and materials.
Stage Focus
BVP is an early-stage investor, bridging the early-stage funding gap for science-based ventures, with follow-on capital reserved for scaling portfolio companies (e.g., Series A/B rounds such as Matisse Pharmaceuticals' Series A and Vertoro's €17M Series B).
Check Size
No specific check-size range is published on the website. BVP's four funds range from €15M (Limburg Ventures, 2004) to €45M (BVP Fund IV, 2021), with €120M raised in total since inception.
Lead Tendency
BVP acts primarily as a lead or co-lead investor, providing catalytic capital to bridge early-stage funding gaps and structuring investments alongside syndicates of trusted partners (e.g., RVO, LIOF, Bio&Tech Smart Capital).
Recent Activity
BVP Fund IV (2021, €45M) is actively investing, closely collaborating with the Rijksdienst voor Ondernemend Nederland (RVO), which provided a €10M seed capital facility. Recent deal activity (September 2026) includes a Series A close for Matisse Pharmaceuticals, a €1M raise for Greencovery, a €2.6M raise for Gravity Gardens, and a seed extension for Healthplus.ai alongside Bio&Tech Smart Capital. Silicozyme emerged from stealth in July 2026 backed by BVP and LIOF. Vertoro closed a €17M Series B in June 2026. On the exit side, SHS Capital acquired a majority stake in Basic Pharma in July 2026.
Portfolio Highlights
BVP's portfolio spans 48 companies (12 AgriFood, 28 Health, 14 Renewable Chemistry, with overlaps), including Vivalyx, Qorium, Kipster, Fortimedix Surgical, ReSolved Technologies, Psylaris, PL BioScience, Grassa, Circularise, Corporis Medical, S&dB, and Healthplus.ai. Historical exits realized by BVP's predecessor funds (Chemelot Ventures and Limburg Ventures) include sales to Fresenius Kabi, Medtronic, LyondellBasell, BASF, Lonza, and SHS Capital. Fortimedix Surgical was acquired by Medtronic in 2024.
Team
BVP describes itself as a close-knit, hands-on team of scientists, operators, and investors:
- Carmel van den Berk — Principal
- Casper Bruens — Partner (DSM/dsm-firmenich corporate venturing background; co-founder of BVP)
- Kim de Boer — Partner (ex-Fund Manager, Triodos Renewables Europe Fund; ex-ING)
- Lex Westbroek — Investment Manager
- Luc Starmans — Partner (ex-KPMG Health & Life Sciences strategy; PhD Biomedical Engineering)
- Marcel Kloosterman — Partner (ex-DSM Life Sciences, corporate venture capital)
- Marcel Lubben — Venture Partner
- Marcel Zijp — Principal
- Pierpaolo Padula — Principal
- Roel van Wegberg — CFO & Partner (promoted to Partner April 2026; joined 2024 from Axis Retail Partners/Generali Investments)
- Silvia Hüntemann — Office Manager
Decision Process
BVP operates as a partnership of partners, principals, and an investment manager rather than a solo GP or formal investment committee structure disclosed publicly.
Founder Preferences
BVP backs "outlier founders building scalable companies that strengthen essential societal systems" — typically technical or scientific founders translating deep research into commercial products, who need support navigating regulation, infrastructure, market dynamics, and long adoption cycles.
Geographic Focus
BVP Fund IV focuses on Benelux and Germany; the Brightlands Agrifood Fund focuses on the Netherlands; Chemelot Ventures and Limburg Ventures are regional (Limburg, Netherlands) funds. The firm reports geographic coverage across 6 countries spanning the EU and US, and is headquartered at the Brightlands Chemelot Campus in Geleen, Netherlands (formerly known through predecessor entity Chemelot Ventures / Limburg Ventures).
Funds
BVP has raised four funds since 2004: Limburg Ventures (2004, €15M, regional, 23 portfolio companies), Chemelot Ventures (2014, €40M, regional, 18 portfolio companies), Brightlands Agrifood Fund (2021, €20M, Netherlands, 8 portfolio companies, fully allocated), and BVP Fund IV (2021, €45M, Benelux and Germany, 12 portfolio companies, actively investing). A successor to the Brightlands Agrifood Fund is currently in formation.